title: Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice.
abstract: DNA coding for murine interleukin 12 (IL-12) prevents the formation of B16-melanoma metastasis when administered intramuscularly. Here, the antitumor effect of IL-12-encoding DNA on established mouse B16 melanoma and human melanoma tumors was investigated in vivo using two animal models: B16 melanoma in C57B/6 mice and human melanoma in nude mice. In B16 melanoma, intratumoral injections of IL-12-encoding DNA resulted in highly significant growth retardation when compared with mice injected with control vector. In the case of the human melanoma model, treatment with DNA coding for IL-12 induced regression of tumors in all cases, with complete disappearance of the tumor in two out of five animals. DNA treatment did not induce systemic side-effects. In the animals injected with control vector the human melanoma tumors grew expansively. The therapeutic effect of the DNA injection was mediated in part by natural killer (NK) cells as shown by NK-depletion experiments. An antivascular effect of IL-12 treatment was evident in histological examination with endothelial thickening and abrupt changes in vessel diameters. These results suggest that intratumoral plasmid DNA coding for IL-12 holds some promise as a new therapeutic tool for accessible melanoma lesions and should be tested in clinical trial.
authors.affiliation: Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
authors.forename: Lucie
authors.initials: L
authors.lastname: Heinzerling
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.forename: Jovan
authors.initials: J
authors.lastname: Pavlovic
authors.forename: Jan
authors.initials: J
authors.lastname: Schultz
authors.forename: Günter
authors.initials: G
authors.lastname: Burg
authors.forename: Karin
authors.initials: K
authors.lastname: Moelling
mesh_terms: D000818:Animals; D002455:Cell Division / Q000187:drug effects; D015316:Genetic Therapy; D006801:Humans; D018664:Interleukin-12 / Q000235:genetics* / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D008212:Lymphocyte Depletion; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D008546:Melanoma, Experimental / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D010957:Plasmids; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D011994:Recombinant Proteins; D018664:Interleukin-12